Cognition Therapeutics Secures Second Philanthropic Donation to Extend Zervimesine Access for DLB Patients
Event summary
- Cognition Therapeutics received a second philanthropic donation from Jeffrey Pechter, founding partner of Mindful Capital, to extend its expanded access program (EAP) for zervimesine in dementia with Lewy bodies (DLB).
- The EAP, now funded for two years, includes 32 participants receiving 100 mg of once-daily oral zervimesine.
- The initial EAP funding came from the family of a DLB patient treated in the Phase 2 SHIMMER study.
- Cognition plans to meet with the FDA in Q2 2026 to discuss next steps for a registrational program evaluating zervimesine in DLB psychosis.
The big picture
The extension of the EAP for zervimesine highlights the critical unmet need in DLB, a condition with no approved treatments. Philanthropic funding is enabling continued access to the investigational therapy while Cognition navigates the regulatory pathway for broader approval. The strategic focus on DLB psychosis aligns with the company's goal of addressing neurodegenerative diseases with high market potential and significant patient burden.
What we're watching
- Regulatory Pathway
- How the FDA meeting in Q2 2026 will shape the design and timeline of the registrational program for zervimesine in DLB psychosis.
- Clinical Data
- Whether long-term data from the EAP will provide additional efficacy and safety signals for zervimesine.
- Funding Strategy
- The pace at which Cognition can secure additional philanthropic or grant funding to support further clinical development.
Related topics